Compare CRCT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRCT | ALLO |
|---|---|---|
| Founded | 1969 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.7M | 738.4M |
| IPO Year | 2021 | 2018 |
| Metric | CRCT | ALLO |
|---|---|---|
| Price | $3.99 | $2.00 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | $3.00 | ★ $8.35 |
| AVG Volume (30 Days) | 464.0K | ★ 6.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 22.20% | N/A |
| EPS Growth | 20.69 | ★ 34.09 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $708,780,000.00 | N/A |
| Revenue This Year | $0.08 | N/A |
| Revenue Next Year | $0.98 | $142,416.42 |
| P/E Ratio | $39.85 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.74 | $0.99 |
| 52 Week High | $7.33 | $4.46 |
| Indicator | CRCT | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 41.10 | 41.17 |
| Support Level | $3.82 | $1.85 |
| Resistance Level | $4.68 | $2.71 |
| Average True Range (ATR) | 0.20 | 0.14 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 16.05 | 28.18 |
Cricut Inc designs and builds a creativity platform that enables users to turn ideas into professional-looking handmade goods. With its connected machines, design apps and accessories, and materials, the users create everything from personalized birthday cards, mugs and T-shirts to large-scale interior decorations. It has two segments including the Platform segment which derives revenue from monthly and annual subscription fees, purchases of digital content, and a minimal amount of the revenue allocated to unspecified future upgrades and enhancements related to the essential software and access to the Company's cloud-based services and Products segment which derives revenue from the sale of its connected machine hardware, and sale of craft, DIY, home decor products and extensions.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).